Cargando…
Gene Panel Tumor Testing in Ovarian Cancer Patients Significantly Increases the Yield of Clinically Actionable Germline Variants beyond BRCA1/BRCA2
SIMPLE SUMMARY: Germline and somatic variant testing of the BRCA1 and BRCA2 genes are important to predict treatment response to PARP inhibitors in ovarian cancer patients. However, germline variants in other genes besides BRCA1 and BRCA2 are associated with ovarian cancer predisposition, which woul...
Autores principales: | Barbosa, Ana, Pinto, Pedro, Peixoto, Ana, Guerra, Joana, Pinto, Carla, Santos, Catarina, Pinheiro, Manuela, Escudeiro, Carla, Bartosch, Carla, Silva, João, Teixeira, Manuel R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650720/ https://www.ncbi.nlm.nih.gov/pubmed/33008098 http://dx.doi.org/10.3390/cancers12102834 |
Ejemplares similares
-
Tumor Testing for Somatic and Germline BRCA1/BRCA2 Variants in Ovarian Cancer Patients in the Context of Strong Founder Effects
por: Peixoto, Ana, et al.
Publicado: (2020) -
Combined germline and tumor mutation signature testing identifies new families with NTHL1 tumor syndrome
por: Pinto, Carla, et al.
Publicado: (2023) -
Next Generation Sequencing of Tumor and Matched Plasma Samples: Identification of Somatic Variants in ctDNA From Ovarian Cancer Patients
por: Barbosa, Ana, et al.
Publicado: (2021) -
Analysis of Founder Mutations in Rare Tumors Associated With Hereditary Breast/Ovarian Cancer Reveals a Novel Association of BRCA2 Mutations with Ampulla of Vater Carcinomas
por: Pinto, Pedro, et al.
Publicado: (2016) -
Frequency of CDH1, CTNNA1 and CTNND1 Germline Variants in Families with Diffuse and Mixed Gastric Cancer
por: Guerra, Joana, et al.
Publicado: (2023)